{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:37Z","timestamp":1707525157084},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,31]]},"DOI":"10.7759\/cureus.39797","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T21:05:14Z","timestamp":1685567114000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Pertuzumab-Induced Toxic Epidermal Necrolysis"],"prefix":"10.7759","author":[{"given":"Mohamed Zakee","family":"Mohamed Jiffry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Carmona Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A","family":"Perozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Napat","family":"Rangsipat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tabares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2157-7","article-title":"Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis","volume":"135","author":"Drucker AM","year":"2012","unstructured":"Drucker AM, Wu S, Dang CT, Lacouture ME. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012, 135:347-54. 10.1007\/s10549-012-2157-7","journal-title":"Breast Cancer Res Treat"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.153436","article-title":"A case report on toxic epidermal necrolysis with etoricoxib","volume":"47","author":"Kameshwari JS","year":"2015","unstructured":"Kameshwari JS, Devde R. A case report on toxic epidermal necrolysis with etoricoxib. Indian J Pharmacol. 2015, 47:221-3. 10.4103\/0253-7613.153436","journal-title":"Indian J Pharmacol"},{"key":"ref3","article-title":"Toxic epidermal necrolysis in a female with metastatic breast cancer treated with vinorelbine","volume":"30","author":"Bazine A","year":"2017","unstructured":"Bazine A, Fetohi M, Namad T, El Benaye J, Ennouhi MA, Mahfoud T, Ichou M. Toxic epidermal necrolysis in a female with metastatic breast cancer treated with vinorelbine. Ann Burns Fire Disasters. 2017, 30:261-3.","journal-title":"Ann Burns Fire Disasters"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy S","year":"2008","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M, et al.. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008, 58:25-32. 10.1016\/j.jaad.2007.08.036","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr T","year":"2010","unstructured":"Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010, 5:39. 10.1186\/1750-1172-5-39","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu DY","year":"2016","unstructured":"Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016, 136:1387-97. 10.1016\/j.jid.2016.03.023","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology","volume":"25","author":"Rosen AC","year":"2014","unstructured":"Rosen AC, Balagula Y, Raisch DW, et al.. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014, 25:225-34. 10.1097\/CAD.0000000000000032","journal-title":"Anticancer Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa A","year":"2020","unstructured":"Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020, 9:10.12688\/f1000research.24748.1","journal-title":"F1000Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt M","year":"2011","unstructured":"Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011, 7:803-13; quiz 814-5. 10.1586\/eci.11.66","journal-title":"Expert Rev Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2013.05.002","article-title":"Pertuzumab in breast cancer: a systematic review","volume":"13","author":"Zagouri F","year":"2013","unstructured":"Zagouri F, Sergentanis TN, Chrysikos D, et al.. Pertuzumab in breast cancer: a systematic review. Clin Breast Cancer. 2013, 13:315-24. 10.1016\/j.clbc.2013.05.002","journal-title":"Clin Breast Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the management of gout","volume":"72","author":"FitzGerald JD","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al.. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care Res (Hoboken). 2020, 72:744-60. 10.1002\/acr.24180","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_583_17","article-title":"Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines!","volume":"63","author":"Kumar R","year":"2018","unstructured":"Kumar R, Das A, Das S. Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines!. Indian J Dermatol. 2018, 63:117-24. 10.4103\/ijd.IJD_583_17","journal-title":"Indian J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/157918-a-rare-case-of-pertuzumab-induced-toxic-epidermal-necrolysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:02Z","timestamp":1707509042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/157918-a-rare-case-of-pertuzumab-induced-toxic-epidermal-necrolysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.39797","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}